BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 35373505)

  • 21. Up-regulation of FOXM1 by E6 oncoprotein through the MZF1/NKX2-1 axis is required for human papillomavirus-associated tumorigenesis.
    Chen PM; Cheng YW; Wang YC; Wu TC; Chen CY; Lee H
    Neoplasia; 2014 Nov; 16(11):961-71. PubMed ID: 25425970
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Relationship between Expression of TGF-β1, Smad2, Smad4 and Prognosis 
of Patients with Resected Non-small Cell Lung Cancer].
    Xie M; He C; Wei S
    Zhongguo Fei Ai Za Zhi; 2015 Sep; 18(9):543-8. PubMed ID: 26383977
    [TBL] [Abstract][Full Text] [Related]  

  • 23. DRD1 suppresses cell proliferation and reduces EGFR activation and PD-L1 expression in NSCLC.
    Grant CE; Flis AL; Toulabi L; Zingone A; Rossi E; Aploks K; Sheppard H; Ryan BM
    Mol Oncol; 2024 Jun; 18(6):1631-1648. PubMed ID: 38572507
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Prognostic Value of Measuring PD-L1 mRNA Expression Levels in Surgically Resected Non-Small Cell Lung Cancer.
    Kim GJ; Lee JH; Park WJ; Lee HW; Hwang IS; Lee DH
    Ann Clin Lab Sci; 2019 May; 49(3):317-323. PubMed ID: 31308030
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Correlation between Programmed Death Ligand-1(PD-L1) Expression and Driver Gene Mutations in Non-Small Cell Lung Carcinoma- Adenocarcinoma Phenotype.
    Pandey RK; Shukla S; Husain N; Islam MH; Hadi R; Kant Tripathi S; Singhal A
    Asian Pac J Cancer Prev; 2022 Jan; 23(1):131-142. PubMed ID: 35092381
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy of anti-PD-1 antibodies in NSCLC patients with an EGFR mutation and high PD-L1 expression.
    Masuda K; Horinouchi H; Tanaka M; Higashiyama R; Shinno Y; Sato J; Matsumoto Y; Okuma Y; Yoshida T; Goto Y; Yamamoto N; Ohe Y
    J Cancer Res Clin Oncol; 2021 Jan; 147(1):245-251. PubMed ID: 32705363
    [TBL] [Abstract][Full Text] [Related]  

  • 27. IL-17A promotes tumorigenesis and upregulates PD-L1 expression in non-small cell lung cancer.
    Liao H; Chang X; Gao L; Ye C; Qiao Y; Xie L; Lin J; Cai S; Dong H
    J Transl Med; 2023 Nov; 21(1):828. PubMed ID: 37978543
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immune Marker Profiling and Programmed Death Ligand 1 Expression Across NSCLC Mutations.
    Toki MI; Mani N; Smithy JW; Liu Y; Altan M; Wasserman B; Tuktamyshov R; Schalper K; Syrigos KN; Rimm DL
    J Thorac Oncol; 2018 Dec; 13(12):1884-1896. PubMed ID: 30267840
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinicopathological and molecular characteristics associated with PD-L1 expression in non-small cell lung cancer: a large-scale, multi-center, real-world study in China.
    Zheng Q; Huang Y; Zeng X; Chen X; Shao S; Jin Y; Xue Q; Wang Y; Guo Y; Gu B; Wu C; Li Y
    J Cancer Res Clin Oncol; 2021 May; 147(5):1547-1556. PubMed ID: 33196892
    [TBL] [Abstract][Full Text] [Related]  

  • 30. LncRNA MALAT1 contributes to non-small cell lung cancer progression via modulating miR-200a-3p/programmed death-ligand 1 axis.
    Wei S; Wang K; Huang X; Zhao Z; Zhao Z
    Int J Immunopathol Pharmacol; 2019; 33():2058738419859699. PubMed ID: 31240979
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A combination of anti-PD-L1 mAb plus Lm-LLO-E6 vaccine efficiently suppresses tumor growth and metastasis in HPV-infected cancers.
    Lin PL; Cheng YM; Wu DW; Huang YJ; Lin HC; Chen CY; Lee H
    Cancer Med; 2017 Sep; 6(9):2052-2062. PubMed ID: 28795532
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [A Real-world Study on the Assessment of Pathological Characteristics and Targeted Therapeutic Effect of Non-small Cell Lung Cancer Patients with Positive Driving Genes and High PD-L1 Expression].
    Zhang H; Yang X; Li K; Wang J; Lv J; Li X; Zhang X; Qin N; Zhang Q; Wu Y; Ma L; Gai F; Hu Y; Zhang S
    Zhongguo Fei Ai Za Zhi; 2021 Feb; 24(2):78-87. PubMed ID: 33478196
    [TBL] [Abstract][Full Text] [Related]  

  • 33. N
    Liu Z; Wang T; She Y; Wu K; Gu S; Li L; Dong C; Chen C; Zhou Y
    Mol Cancer; 2021 Aug; 20(1):105. PubMed ID: 34416901
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Silibinin Regulates Tumor Progression and Tumorsphere Formation by Suppressing PD-L1 Expression in Non-Small Cell Lung Cancer (NSCLC) Cells.
    Rugamba A; Kang DY; Sp N; Jo ES; Lee JM; Bae SW; Jang KJ
    Cells; 2021 Jun; 10(7):. PubMed ID: 34209829
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Therapy-induced E-cadherin downregulation alters expression of programmed death ligand-1 in lung cancer cells.
    Suda K; Rozeboom L; Rivard CJ; Yu H; Ellison K; Melnick MAC; Hinz TK; Chan D; Heasley LE; Politi K; Mitsudomi T; Hirsch FR
    Lung Cancer; 2017 Jul; 109():1-8. PubMed ID: 28577937
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical significance of ≥ 50% PD-L1 expression with the SP263 monoclonal antibody in non-small cell lung cancer patients.
    Li W; Song P; Guo L; Liu X; Guo C; Ying J; Gao S
    Thorac Cancer; 2019 Feb; 10(2):175-182. PubMed ID: 30536734
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Membrane-Associated RING-CH 8 Functions as a Novel PD-L1 E3 Ligase to Mediate PD-L1 Degradation Induced by EGFR Inhibitors.
    Qian G; Guo J; Vallega KA; Hu C; Chen Z; Deng Y; Wang Q; Fan S; Ramalingam SS; Owonikoko TK; Wei W; Sun SY
    Mol Cancer Res; 2021 Oct; 19(10):1622-1634. PubMed ID: 34183449
    [TBL] [Abstract][Full Text] [Related]  

  • 38. EGFR-TKI resistance promotes immune escape in lung cancer via increased PD-L1 expression.
    Peng S; Wang R; Zhang X; Ma Y; Zhong L; Li K; Nishiyama A; Arai S; Yano S; Wang W
    Mol Cancer; 2019 Nov; 18(1):165. PubMed ID: 31747941
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Reduction of microRNA-184 by E6 oncoprotein confers cisplatin resistance in lung cancer via increasing Bcl-2.
    Tung MC; Lin PL; Cheng YW; Wu DW; Yeh SD; Chen CY; Lee H
    Oncotarget; 2016 May; 7(22):32362-74. PubMed ID: 27083050
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Programmed death-ligand 1 expression associated with molecular characteristics in surgically resected lung adenocarcinoma.
    Song Z; Yu X; Cheng G; Zhang Y
    J Transl Med; 2016 Jun; 14(1):188. PubMed ID: 27342566
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.